Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma

Despite recent advances, multiple myeloma (MM) remains incurable, and most patients eventually develop progressive disease. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) offers a potentially curative option in 10%-20% of patients with relapsed or refractory disease. We evaluated the...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biology of blood and marrow transplantation 2010-08, Vol.16 (8), p.1122-1129
Hauptverfasser:	Efebera, Yvonne A, Qureshi, Sofia R, Cole, Suzanne M, Saliba, Rima, Pelosini, Matteo, Patel, Ronak M, Koca, Ebru, Mendoza, Floralyn L, Wang, Michael, Shah, Jatin, Alousi, Amin, Hosing, Chitra, Popat, Uday, Kebriaei, Partow, Anderlini, Paolo, Khouri, Issa F, Champlin, Richard, Giralt, Sergio, Qazilbash, Muzaffar H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Female Graft vs Host Disease - etiology Hematology, Oncology and Palliative Medicine Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic Stem Cell Transplantation - methods Humans Male Middle Aged Multiple myeloma Multiple Myeloma - therapy Neoplasm Recurrence, Local - therapy Prognosis Reduce intensity allogeneic transplant Relapse/refractory Transplantation Conditioning Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!